𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Precore stop mutant in anti-HBe-positive phases of chronic hepatitis B virus infection

✍ Scribed by Chia-Ming Chu

Book ID
119392559
Publisher
Nature Publishing Group
Year
2002
Tongue
English
Weight
31 KB
Volume
97
Category
Article
ISSN
0002-9270

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prevalence of precore mutants in anti-HB
Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany
✍ Kn�ll, Antje; Rohrhofer, Anette; Kochanowski, Bernd; Wurm, Eva-Maria; Jilg, Wolf 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

Hepatitis B virus (HBV) precore mutants are associated often with highly productive infection in hepatitis B surface antigen (HBsAg) carriers lacking hepatitis B e antigen (HBeAg) but positive for anti-HBe, rendering serological identification of infectious individuals unreliable. Although considere

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60